Simulations Plus

DILIsym application contributes to approval of new drugs for migraine treatment

New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements

FDA Renewal Ensures Access for DILIsym Evaluation of Drug Candidate Submissions

Collaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables

Funded partnership with large pharmaceutical company will enhance mechanistic dissolution models for injectable formulations

Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40%
Board of Directors announces quarterly dividend of $0.06 per share

SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform

Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development

Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET

Improving access to treatment in the lives of individuals and families affected by rare diseases

New functionality for transdermal products creates a state-of-the-art IVIVE methodology in combination with the GastroPlus TCAT platform

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy,

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech

Collaborative research effort will further enhance the ACAT model to aid scientists in the detailed understanding of local drug disposition in the gastrointestinal tract

Partnership will expand virtual animal models to support veterinary medicine and next-generation alternatives to animal testing